Tripeptide-29

What is Tripeptide-29?

Tripeptide-29 is the cosmetic INCI designation for the collagen-derived tripeptide glycyl-prolyl-hydroxyproline (Gly-Pro-Hyp, commonly abbreviated GPH). The sequence is not arbitrary — (Gly-Pro-Hyp) is the most abundant repeating tripeptide motif in type I collagen, the triple-helical building block that gives collagen its characteristic hydroxyproline content and its ability to form stable fibrils. As an ingredient, Tripeptide-29 is used in topical cosmetic formulations positioned as collagen-supporting actives; separately, the same tripeptide is generated during digestion of oral collagen hydrolysate and appears measurably in human plasma after collagen peptide supplementation. It is important to distinguish two distinct evidence contexts: (1) topical Tripeptide-29 as a cosmetic INCI ingredient, where dedicated clinical efficacy data is thin, and (2) oral collagen peptide mixtures containing GPH (alongside many other di- and tripeptides), where human RCT data on skin elasticity, hydration, and joint outcomes is substantially stronger. The oral evidence does not directly validate the topical ingredient.

What Tripeptide-29 Is Investigated For

Tripeptide-29 (Gly-Pro-Hyp) sits at an awkward intersection: it is both a cosmetic INCI ingredient used topically and a naturally occurring digestion product of oral collagen peptide supplements that reaches the bloodstream and can be measured in plasma after ingestion. Those two contexts have very different evidence bases. The topical cosmetic use of Tripeptide-29 as an INCI-labeled active has thin direct clinical data — mostly in vitro fibroblast work and supplier-associated formulation studies, with essentially no independent human RCT specifically testing isolated topical Tripeptide-29 on objective skin endpoints. The oral context is different: collagen hydrolysate and specific collagen peptide products (containing GPH alongside Pro-Hyp, Hyp-Gly, and other di/tripeptides) have a growing body of randomized placebo-controlled trials showing modest but statistically significant improvements in skin elasticity, hydration, wrinkle depth, and joint symptoms over 8–24 weeks. Honest framing matters: those oral trials are not tests of topical Tripeptide-29. They test complex peptide mixtures delivered systemically, in which GPH is one of several bioactive fragments. Treating the oral evidence as validation for the topical ingredient would overstate the case.

How It Works

Tripeptide-29 is the cosmetic name for Gly-Pro-Hyp — a three-amino-acid fragment that happens to be the most common building block of collagen itself. The idea behind using it topically or as part of oral collagen peptide supplements is that this fragment may act as a signal that tells skin cells to rebuild collagen. For oral collagen peptides, there is decent human trial evidence for skin and joint benefits, but those trials test complex mixtures, not isolated Tripeptide-29. For the topical cosmetic ingredient specifically, direct clinical evidence is thin.

Gly-Pro-Hyp (GPH) is the most abundant repeating tripeptide in type I collagen's characteristic (Gly-X-Y)n triple-helix, where Y is most commonly 4-hydroxyproline. Two mechanistic frames are relevant: (1) Matrix-mimetic / matrikine framing. Collagen-derived fragments released during extracellular matrix turnover are proposed to act as "matrikines" — signals to fibroblasts that matrix remodeling is underway. In vitro work with collagen-derived peptides including GPH has shown upregulation of collagen gene expression, fibroblast proliferation, and hyaluronic acid production in cultured dermal fibroblasts, though the specific receptor or signaling cascade for GPH is less well characterized than for Matrixyl's KTTKS (TGF-β-related) or GHK-Cu (multiple gene-expression effects including copper-dependent enzyme modulation). Whether the in vitro activity reflects a dedicated receptor, a generic amino-acid-availability effect, or a ligand-mediated signal remains an open question. (2) Oral-supplement bioavailability framing. Unlike most peptides (which are rapidly hydrolyzed in the gut), GPH and related collagen-derived di-/tripeptides (notably Pro-Hyp and Hyp-Gly) partially resist digestion and appear measurably in human plasma after oral collagen hydrolysate ingestion. Plasma GPH peaks within 1–2 hours of ingestion at nanomolar-to-low-micromolar concentrations and is thought to be transported intact via PEPT1 (the proton-coupled oligopeptide transporter). This gives the oral collagen peptide category a plausible systemic signaling story that distinguishes it from intact dietary protein. Human RCTs of oral collagen peptide products show modest but replicable improvements in skin elasticity and hydration (pooled effect sizes in meta-analysis) and joint pain / function outcomes in osteoarthritis trials. These trials do not isolate GPH from the other bioactive fragments in the mixture. For topical Tripeptide-29 as an INCI cosmetic ingredient, the mechanistic case is effectively (1) above — the oral bioavailability context in (2) is not operative for topical application.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Tripeptide-29:

• 01Topical isolated-active human RCT — no published independent randomized controlled trial has tested topical Tripeptide-29 alone at a defined concentration against placebo with objective skin endpoints. The clinical case for topical use rests on extrapolation from the oral-collagen-peptide literature, which tests mixtures rather than the isolated ingredient.
• 02Topical skin penetration — quantitative penetration data for an unmodified hydrophilic tripeptide through intact stratum corneum is limited; vehicle and any encapsulation matter substantially for delivered dose.
• 03Disaggregating the oral collagen peptide effect — published RCTs and meta-analyses of oral collagen hydrolysate test complex peptide mixtures. How much of the observed skin and joint benefit is attributable to GPH specifically versus Pro-Hyp, Hyp-Gly, or other bioactive fragments has not been cleanly resolved.
• 04Long-term consequences of sustained exogenous matrix-mimetic signaling — whether chronic delivery of collagen-derived fragments has any unintended effects on fibroblast biology (senescence, dedifferentiation, fibrotic skew) over years of use is uncharacterized.
• 05Head-to-head comparison with other cosmetic collagen-targeting peptides — direct comparisons of Tripeptide-29 against Matrixyl, GHK-Cu, or Palmitoyl Tripeptide-1 at clinically meaningful doses are absent.
• 06Receptor identity — whether topical Tripeptide-29 engages a specific surface receptor on fibroblasts, signals via a generic amino-acid-availability effect, or both is not established.

Forms & Administration

Topical cosmetic formulations (serums, creams) are the primary route for the INCI-labeled Tripeptide-29 ingredient. It is typically included alongside other cosmetic actives (hyaluronic acid, niacinamide, other peptides) rather than as a standalone active. The related oral category — collagen hydrolysate and bioactive collagen peptide supplements — is a separate product class sold as a powder or drink mix, typically dosed at 2.5–10 g of collagen peptides daily, where GPH is one of many peptide fragments present. Injection is not an established route for Tripeptide-29; cosmetic formulations are not sterile injectable products and there is no published rationale or safety basis for injecting them.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions